Acacia Research subsidiary acquires rights to intraluminal device technology patent

Acacia Research Corporation (Nasdaq:ACTG) announced today that a subsidiary has acquired the rights to a patent for intraluminal device technology.

“Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios”

"As Acacia's licensing success grows, more patent owners are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios," concluded Mr. Ryan.

This patented technology generally relates to securing intraluminal devices, such as stent grafts, in the body.